SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated May 7, 2025, reports a transaction in the company's own shares. The filing discloses a share repurchase executed on May 6, 2025, pursuant to a non-discretionary agreement with Citigroup Global Markets Limited entered into on February 24, 2025.
Key Financial Metrics and Transaction Details
- Shares Purchased: 700,707 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,440.00 GBp; highest price paid was 1,469.50 GBp.
- Average Price: Volume-weighted average price paid was 1,451.03 GBp.
- Trading Venue: All transactions occurred on the London Stock Exchange (XLON).
- Treasury Shares: Following this purchase, GSK holds 206,910,114 ordinary shares in treasury.
- Shares Outstanding: 4,108,336,388 ordinary shares are in issue (excluding treasury shares).
- Voting Rights: Total voting rights stand at 4,108,336,388.
Material Changes and Program Progress
This transaction is part of GSK's existing buyback programme. Since the commencement of the current agreement on February 24, 2025, the company has purchased an aggregate of 37,839,811 ordinary shares. The filing does not provide comparative financial performance metrics (revenue, profit, cash flow) as it is a disclosure of a specific capital transaction rather than a periodic financial report.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and its Q1 Results for 2025. No new guidance or management commentary regarding operational outlook is provided in this specific filing.
Investor Verification Checklist
- Verify the total number of treasury shares held (206,910,114) against the company's latest capitalization table.
- Confirm the remaining authorization under the buyback programme initiated on February 24, 2025.
- Review the "Risk Factors" section of the 2024 Form 20-F and Q1 2025 results for context on the buyback strategy.
- Check the denominator for shareholder notification thresholds under FCA Disclosure Guidance and Transparency Rules (4,108,336,388 voting rights).